- Details
- (Length of Conversation: 15 min) Andrew Armstrong and Alicia Morgans, discuss the PROPHECY trial, a prospective trial of circulating tumor cells, evaluating two current assays: the EPIC AR-V7 Nuclear Protein CTC and the Hopkins AR-V7 Adnatest. The conversation evolves to a discussion of the data from Armstrong's recent work shared at the 2018 ASCO GU meeting: measuring osteomimicry in three levels...
|
- Details
- (Length of Discussion: 10 min) Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion wiht Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 dif...
|
- Details
- (Length of Conversation: 11 minutes) Charles Ryan, MD and Oliver Sartor, MD cover three interesting topics in prostate cancer. Oliver provides his view on potential clinical implications relative to the ERA 223 phase 3 trial with Radium-223. Discussion ensues on novel nuclear medicine approaches to treating prostate cancer including Lutetium 177 PSMA and Actinium PSMA-225. Lastly, a concise review...
|
- Details
- (Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...
|
- Details
- Professor Anwar Padhani discusses the value of whole body MRI scanning in diagnosing disease progression at the Radiological Society of North America (RSNA) 2017 conference. Dr. Padhani discusses the biggest advantage of using whole body MRI scanning versus bone or CT scans, which is the ability to detect metastatic disease in bone. Whole body MRI scans are also accurate in detecting castrate-resi...
|
- Details
- (Length of lecture - 30 minutes) Dr. Neal Shore discusses the evolving interest in Alpha-Emitting Radionuclide Therapy over the past 20 years, which is due to advances in the targeted delivery of radionuclides as well as increased availability of many different alpha emitters. These developments have led to a number of clinical trials in this space, particularly with Radium-223 , which is the only...
|
- Details
- David Crawford, MD discusses with Thomas Keane, MD, the paper, RADAR II: The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer, which was designed to offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostat...
|
- Details
- Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. (Length of lecture 57 minutes) In this lecture, David Schuster describes the mechanisms of uptake of the PET radiotracer fluciclovine and identifies normal biodistribution of fluciclovine. In addition, Dr. Schuster discusses the FDA approval and clinical indication of fluciclovine and the clinical inter...
|
- Details
- Read the complete conference coverage of: 10th International Symposium on Targeted Alpha Therapy, TAT-10 Commentary on the presentation: TAT-10 Special Lunchtime Seminar: Radium 223 from Bench to Bedside, and Future Directions for Targeted Alpha Therapy Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned : EVERYDAY UROLOGY- Full Text Arti...
|
- Details
- E. David Crawford interviews Phillip Koo on the RADAR II paper and the key take-aways from the perspective of a nuclear medicine physician treating mCRPC. Biographies: Phillip Koo, MD E. David Crawford, MD
|
